-
OncoTargets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
Review
(2388) Views (2369) Full article downloads
Authors: Anita Schwandt1, Laura S Wood1, Brian Rini1,2, Robert Dreicer1,2
Published Date March 2009
Volume 2009:2 Pages 51 - 61
DOI: http://dx.doi.org/10.2147/OTT.S4052
Anita Schwandt1, Laura S Wood1, Brian Rini1,2, Robert Dreicer1,2
1Department of Solid Tumor Oncology; 2Taussig Cancer Institute and the Glickman Urological and Kidney Institute; Cleveland Clinic, Cleveland OH, USA
Abstract: Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and has demonstrated impressive antitumor activity in phase II and subsequently improvement in progression free survival in phase III renal cancer trials. We review the unique side effects of sunitinib therapy with emphasis on establishing effective patient education for anticipation and early management of therapy-related side effects.
Keywords: sunitinib, renal cell carcinoma, side effects, tyrosine kinase inhibitor
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Intranet access to all Dove journals
If you would like your institutional intranet to have access to the Dove Medical Press journals please contact me.
- Epigenomics in cancer management
- Intercellular cancer collisions generate an ejected crystal comet tail effect with fractal interface embryoid body reassembly transformation
- Topotecan in the treatment of relapsed small cell lung cancer
- Role of trabectedin in the treatment of soft tissue sarcoma
